Skip to main content
. 2024 Jul 14;5(10):100706. doi: 10.1016/j.jtocrr.2024.100706

Figure 1.

Figure 1

Quantitative immunofluorescence detects changes in the immune microenvironment in patients with advanced EGFR-mutant NSCLC treated with afatinib and pembrolizumab. (A) Patient with 20% tumor shrinkage and PFS more than 6 months. Increase in CD3+ T-cells and decrease in tumor proliferation (Ki67) noted. (B) Patient with progression at first interval imaging. No change in CD3+ T-cells or tumor proliferation (Ki67). PFS, progression-free survival.